Nanoly Bioscience

Nanoly Bioscience is a private biotechnology company developing polymer-based stabilization technology designed to reduce or eliminate cold-chain requirements for vaccines, biologics, proteins, viral vectors, and related temperature-sensitive therapeutics. Rather than advancing a conventional therapeutic pipeline, the company appears focused on its DynaShield platform, a biocompatible excipient and polymer network intended to preserve product integrity during storage and shipment. The technology is positioned for use across research samples, human samples, vaccines, and other biologic products, with the goal of improving global access and lowering logistics costs. Nanoly has roots in materials science and the University of Colorado ecosystem, and has raised early-stage funding from investors including Intel Capital and MassChallenge. In February 2026, the company announced a strategic licensing agreement with Bio Usawa centered on DynaShield.